Evercore ISI maintains outperform rating on Vera Therapeutics stock

Evercore ISI reiterated its Outperform rating on Vera Therapeutics (VERA) with a $75 price target, citing optimism regarding upcoming FDA meetings and data releases for atacicept, a potential IgAN treatment. Positive Phase 3 ORIGIN trial results showed a 46% reduction in proteinuria from baseline; however, Vera reported a wider-than-expected Q1 2025 net loss of $0.81 per share. Cantor Fitzgerald maintains an Overweight rating with a $100 price target, reflecting confidence in atacicept's potential.

Analysis

Evercore ISI has reiterated an Outperform rating on Vera Therapeutics (VERA) with a $75.00 price target, substantially above its current $18.95 trading price, reflecting optimism around upcoming FDA discussions for accelerated approval of atacicept and pivotal data expected in H2 2025. This bullish sentiment is shared by Cantor Fitzgerald, which maintains an Overweight rating and a $100 price target, with the analyst consensus range spanning $26 to $100. Vera's lead candidate, atacicept, demonstrated a significant 46% reduction in proteinuria from baseline and 42% versus placebo at week 36 in its ORIGIN Phase 3 trial for IgAN, positioning it as a promising treatment; the company plans a Biologics License Application for accelerated approval in Q4 2025. Financially, Vera Therapeutics maintains a robust position, evidenced by a current ratio of 27.68 and holding more cash than debt on its balance sheet. However, the company reported a wider-than-expected net loss of $0.81 per share for the first quarter of 2025, totaling $51.7 million, an increase from $28.4 million in the prior year's quarter and $0.08 above analyst estimates. In the competitive landscape, Otsuka’s sibeprenlimab, another B cell modulator with Phase 3 results recently presented, is anticipated to enter the market 6-9 months ahead of atacicept. Despite strong clinical data and analyst support for VERA, an InvestingPro AI analysis noted the stock was not at the top of its list for massive upside potential, suggesting a degree of caution may be warranted alongside the prevailing optimism.

Key Decisions for Investors

• Investors should weigh the significant upside potential suggested by analyst price targets ($75-$100) and positive atacicept Phase 3 data against the inherent risks of biotech development, Vera's recent widening net loss, and the cautionary note from an InvestingPro AI analysis regarding its relative undervaluation.
• Monitor critical upcoming catalysts such as FDA interactions for atacicept's accelerated approval, full data publication in H2 2025, the planned Biologics License Application in Q4 2025, and competitive dynamics, particularly Otsuka's sibeprenlimab progression.
• Evaluate the company's robust liquidity (current ratio 27.68, net cash position) against its increased Q1 2025 net loss ($0.81 per share) and future capital requirements for advancing atacicept through regulatory approval and potential market launch.